The enhanced immune response of healthy individuals after vaccination with SARS CoV-2 inactivated vaccine, BBIBP-CorV

BBIBP-CorV, an inactivated vaccine, has demonstrated safety, efficacy, and immunogenicity against COVID-19 in in-vitro studies and clinical trials. This study sought to comprehensively understand the development and duration of virus-specific antibodies and characterize the TCR-β repertoire changes in patients with BBIBP-CorV We comprehensively analyzed antibody response, anti- and proinflammatory cytokines concentration, and TCR-β repertoire induced by BBIBP-CorV vaccination in peripheral blood samples from 54 uninfected-vaccinated recipients who were enrolled in the phase 3 trial and 16 healthy donors as well as 54 COVID-19 patients with different disease courses